In particular, we chose to use IFN-β as type I IFN, given the previous data in literature suggesting a negative role for IFN-β in breast cancer stemness [56, 57], and IFN-γ as type II IFN, being the only member of this subfamily. This evidence concerns the gene IFNB1 and breast carcinoma.